RxSight (RXST)
(Delayed Data from NSDQ)
$61.15 USD
+0.56 (0.92%)
Updated May 24, 2024 04:00 PM ET
After-Market: $61.22 +0.07 (0.11%) 7:42 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
RXST 61.15 +0.56(0.92%)
Will RXST be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RXST based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RXST
Buy 5 Medical Instruments Stocks to Enhance Your Portfolio
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
RXST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
What's in the Offing for Brainsway (BWAY) in Q4 Earnings?
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
Other News for RXST
Do You Have Your Eye On Vision Care Stocks?
RxSight, Inc. Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
What's Driving Establishment Labs Holdings Inc's Surprising 34% Stock Rally?
J.P. Morgan Sticks to Its Buy Rating for RxSight (RXST)
RxSight price raises equity at $56 per share